Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
08 Mayo 2024 - 1:30AM
Abivax announces presentation of four abstracts for
obefazimod in ulcerative colitis and preclinical colon cancer model
at Digestive Disease Week 2024
PARIS, France, May 8, 2024, 8:30 a.m.
CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX)
(“Abivax” or the “Company”), a clinical-stage biotechnology company
focused on developing therapeutics that harness the body’s natural
regulatory mechanisms to stabilize the immune response in patients
with chronic inflammatory diseases, today announced that four
scientific abstracts on its lead drug candidate, obefazimod, for
the treatment of moderately to severely active ulcerative colitis
(UC) and in a preclinical model on colon cancer, will be presented
at Digestive Disease Week (DDW) as part of scientific exchange,
taking place May 18-21, 2024, in Washington D.C., U.S.
“With four abstracts accepted for presentation
at DDW 2024, we look forward to our continued exchange with the IBD
community around the emerging clinical profile of obefazimod,” said
Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
“We are excited to share new preclinical data showing obefazimod’s
impact in reducing the number of tumors in the azoxymethane
(AOM)/dextran sodium sulfate (DSS) mouse model of
colitis-associated cancer—data in support of obefazimod’s novel
mechanism of action.”
For more information, visit the Abivax booth at
the DDW exhibitor hall (booth #529) or see congress details on the
DDW website.Obefazimod data to be presented:
Presentation Title |
Session |
Presenter |
Presentation/ Session Number |
Session Hall |
Date and Time (EDT) |
Oral Presentation |
Efficacy and safety of obefazimod in UC patients at weeks 48 and 96
of an open-label maintenance study among clinical responders at
week 8 of the Phase 2b induction trial |
IBD Controlled Trials II |
Prof. Bruce E. Sands, M.D., M.S.Dr. Burrill B. Crohn Professor of
Medicine and Chief, Dr. Henry D. Janowitz Division of
Gastroenterology, Icahn School of Medicine at Mount Sinai, NY |
|
|
May 21, 20248:00-9:30 a.m. |
Poster Presentations |
Obefazimod and its active metabolites ABX-464-N-Glu act by
stabilizing protein-protein interaction among key RNA biogenesis
partners, CBC and ARS2 |
Cell and Molecular Biology of Gastrointestinal Disorders |
Didier Scherrer, Ph.D. Chief Scientific Officer, Abivax |
|
|
May 18, 202412:30-1:30 p.m. |
Obefazimod reduces total number of tumors and high-grade adenomas
in a murine colitis associated colorectal cancer model |
GI Cancer Research Models: Organoids‚ Engineered Cell and Tissue
Platforms‚ and Animal Models |
Didier Scherrer, Ph.D. Chief Scientific Officer, Abivax |
|
|
May 18, 202412:30-1:30 p.m. |
Efficacy of once-daily, orally administered obefazimod in patients
with moderately to severely active UC at weeks 8, 48, and 96 broken
down by induction treatment dose |
IBD: Controlled Clinical Trials in Humans |
Prof. Bruce E. Sands, M.D., M.S.Dr. Burrill B. Crohn Professor of
Medicine and Chief, Dr. Henry D. Janowitz Division of
Gastroenterology, Icahn School of Medicine at Mount Sinai, NY |
|
|
May 19, 202412:30-1:30 p.m. |
Abivax has also sponsored a Product Theater
presentation titled, “An Investigational New MOA that Can Stabilize
the Inflammatory Response in Ulcerative Colitis,” taking place on
May 20, 2024, at 2:30-3:15 p.m. EDT in room “DDW Theater 1,”
featuring Prof. Parambir S. Dulai, M.D., Associate Professor of
Medicine in the Division of Gastroenterology and Hepatology at
Northwestern University, Evanston, Illinois, U.S.
About ObefazimodObefazimod,
Abivax’s lead investigational drug candidate, is an orally
administered small molecule that was demonstrated to potentially
enhance the expression of a single microRNA, miR-124. Phase 2
clinical trials in patients with UC have generated positive data,
resulting in the initiation of a pivotal global Phase 3 clinical
trial program (ABTECT Program), with first patients enrolled in the
United States in October 2022. Initiation of a Phase 2b
clinical trial in Crohn’s disease is expected in Q3 2024, and
exploration of potential combination therapy opportunities in UC is
ongoing.
About Abivax Abivax is a
clinical-stage biotechnology company focused on developing
therapeutics that harness the body’s natural regulatory mechanisms
to stabilize the immune response in patients with chronic
inflammatory diseases. Based in France and the United States,
Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3
clinical trials for the treatment of moderately to severely active
ulcerative colitis. More information on the Company is available at
www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter,
@Abivax.Contact:
Abivax Investor RelationsPatrick
Malloypatrick.malloy@abivax.com+1 847 987 4878
Abivax Communicationscommunications@abivax.com
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements, forecasts and estimates, including those relating to
the Company’s business and financial objectives. Words such as
“design,” “expect,” “forward,” “future,” “potential,” “plan,”
“project” and variations of such words and similar expressions are
intended to identify forward-looking statements. Although
Abivax’s management believes that the expectations reflected in
such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are
subject to various risks, contingencies and uncertainties,
many of which are difficult to predict and generally beyond the
control of Abivax, that could cause actual results and developments
to differ materially from those expressed in, or implied or
projected by, the forward-looking information and
statements. A description of these risks, contingencies and
uncertainties can be found in the documents filed by the Company
with the French Autorité des Marchés Financiers pursuant to its
legal obligations including its universal registration document
(Document d’Enregistrement Universel) and in our Annual Report on
Form 20-F filed with the U.S. Securities and Exchange Commission on
April 5, 2024 under the caption “Risk Factors.” These risks,
contingencies and uncertainties include, among other things, the
uncertainties inherent in research and development, future clinical
data and analysis, decisions by regulatory authorities, such as the
FDA or the EMA, regarding whether and when to approve any drug
candidate, as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates. Special consideration should be given
to the potential hurdles of clinical and pharmaceutical development
including further assessment by the company and regulatory agencies
and IRBs/ethics committees following the assessment of preclinical,
pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data.
Furthermore, these forward-looking statements, forecasts and
estimates are only as of the date of this press release. Readers
are cautioned not to place undue reliance on these forward-looking
statements. Abivax disclaims any obligation to update these
forward-looking statements, forecasts or estimates to reflect any
subsequent changes that the Company becomes aware of, except as
required by law. Information about pharmaceutical products
(including products currently in development) that is included in
this press release is not intended to constitute an
advertisement. This press release is for information purposes
only, and the information contained herein does not constitute
either an offer to sell, or the solicitation of an offer to
purchase or subscribe securities of the Company in any
jurisdiction. Similarly, it does not give and should not be treated
as giving investment advice. It has no connection with the
investment objectives, financial situation or specific needs of any
recipient. It should not be regarded by recipients as a substitute
for exercise of their own judgment. All opinions expressed herein
are subject to change without notice. The distribution of this
document may be restricted by law in certain jurisdictions. Persons
into whose possession this document comes are required to inform
themselves about and to observe any such restrictions.